ADIL news

Latest 2 stories · newest Aug 17, 2026

ADIL

Adial Reports Q2 2026 Results, Acquires Azora Therapeutics

Adial Pharmaceuticals reported Q2 2026 financial results and announced the acquisition of Azora Therapeutics and a $32 million private placement to advance its Ahr agonist candidate for ulcerative colitis.

Offering|M&A Aug 17, 2026 sentiment 0.00 SEC filing ↗

ADIL

Adial Pharmaceuticals agrees to merge with Azora Therapeutics

Adial Pharmaceuticals signed a merger agreement with Azora Therapeutics, effective June 11, 2026, combining the two pharmaceutical companies. The transaction involves a two-step merger structure with detailed terms for share conversion and consideration exchange.

M&A Jun 11, 2026 sentiment +0.50 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same ADIL feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/ADIL/newsSTART FREE